CIS
SRPT icon

Capital International Sarl’s Sarepta Therapeutics SRPT Stock Holding History

Capital International Sarl’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,598
Closed -$2.34M – 299
2025
Q1 		$2.34M Buy
36,598
+1,342
+4% +$141K 0.05% 187
2024
Q4 		$4.29M Buy
35,256
+16,408
+87% +$2.01M 0.1% 137
2024
Q3 		$2.35M Buy
+18,848
New +$2.61M 0.06% 162
2020
Q2 		– Sell
-50
Closed -$5K – 236
2020
Q1 		$5K Buy
+50
New +$5.71K ﹤0.01% 228

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Capital International Sarl's SRPT Position: Q2 2025 in Review

Capital International Sarl sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 36,598 shares — an estimated $2.34M sold.

Capital International Sarl first reported a position in SRPT in Q1 2020 and held it in 4 quarters. The position peaked at $4.29M in Q4 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Capital International Sarl reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Capital International Sarl sold 36,598 Sarepta Therapeutics shares in Q2 2025, an estimated $2.34M.
  • Capital International Sarl first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 4 quarters.
  • Capital International Sarl's Sarepta Therapeutics position peaked at $4.29M in Q4 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Capital International Sarl's 13F filing for Q2 2025, filed 13 Aug 2025.